Dr. Michael Hayden

Dr. Hayden was appointed to the Board as a Non-Executive Director in July 2021. Dr. Hayden was previously the President of Global R&D and Chief Scientific Officer at Teva Pharmaceuticals Industries Ltd. and has co-founded five biotechnology companies: Prilenia Therapeutics B.V., NeuroVir Therapeutics Inc., Xenon Pharmaceuticals Inc., Aspreva Pharmaceuticals Corp and 89bio, Inc. He currently serves as CEO of Prilenia Therapeutics and represents private and public (Ionis Pharmaceuticals Inc., AbCellera Biologics Inc. and 89Bio Inc.) companies at Board level.

Dr. Hayden has focused his research primarily on translational medicine, including genetics of diabetes, lipoprotein disorders, Huntington’s disease, predictive and personalised medicine, and drug development, and has authored approximately 900 peer-reviewed publications and invited submissions.

Dr. Michael Hayden will not be standing for re-election at the forthcoming Annual General Meeting in June 2024.

Committee Membership:

• Science and Technology Advisory Committee

Relevant Skills:

• Cell and gene therapy
• Scientific advisory
• Drug development